Berenberg upgrades Abbvie stock rating to Buy on successful post-Humira transition

Berenberg upgraded AbbVie (ABBV) to Buy with a $270 price target, up from $170, citing the company's successful navigation of the Humira patent expiry through superior products like Skyrizi and Rinvoq, alongside a strengthened oncology portfolio and improved neuroscience outlook. This bullish view is reinforced by recent strategic moves, including a settlement delaying Rinvoq generic entry until 2037, the acquisition of Gilgamesh Pharmaceuticals for MDD, and positive clinical trial data, all contributing to robust high single-digit growth and strong cash flow generation, with the stock nearing its 52-week high.

Analysis

Berenberg's upgrade of AbbVie (ABBV) to Buy with a substantial price target increase to $270 from $170 underscores a significant shift in analyst perception, driven by the company's successful navigation of the Humira patent cliff. The firm highlights that successor products Skyrizi and Rinvoq are effectively replacing Humira's revenue, a critical de-risking event for the company. This strategic success is complemented by a strengthening oncology portfolio, featuring an expanded hematology franchise and antibody-drug conjugates, and an improved neuroscience outlook via new acquisitions, despite prior setbacks. Recent corporate actions further bolster this positive thesis: a settlement with generic manufacturers extends Rinvoq's U.S. market exclusivity until April 2037, providing long-term revenue visibility, while the planned acquisition of Gilgamesh Pharmaceuticals signals a strategic entry into innovative mental health therapies. With the stock already delivering a 25.05% year-to-date return and trading near its 52-week high, the consensus view, also supported by positive ratings from Piper Sandler and BMO Capital, is that AbbVie's high single-digit growth, strong cash flow, and top-tier R&D returns justify a premium valuation.

Key Decisions for Investors

• Given the successful management of the Humira patent cliff and the extended exclusivity for Rinvoq until 2037, investors should view the primary historical overhang on the stock as significantly mitigated, reinforcing its position as a core biopharmaceutical holding.
• With the stock trading near 52-week highs and multiple analysts raising price targets, momentum is strong; however, investors may want to monitor for potential consolidation or pullbacks before initiating or adding to positions.
• Future performance will be heavily reliant on the commercial execution of Skyrizi and Rinvoq, along with the successful integration of recent acquisitions in neuroscience and oncology; these areas should be the primary focus of ongoing due diligence.
• Investors should consider the declared quarterly dividend of $1.64 per share as a tangible component of total return, supported by the company's strong cash flow generation.